優必選(09880.HK):會積極關注並考慮包括在A股上市各類可能性
據《上海證券報》引述優必選(09880.HK)方面表示,A股和H股上市催生新機遇,不僅讓內地資本市場更具競爭力,也將為新質生產力企業營造更加友好和開放的市場環境。作為在港股上市的人形機械人企業,優必選會積極關注並考慮包括在A股上市的各類可能性,持續探索有利於人形機械人產業長期成長的路徑。
中共中央辦公廳、國務院辦公廳昨日(10日)印發《關於深入推進深圳綜合改革試點 深化改革創新擴大開放的意見》提出,允許在香港聯交所上市的粵港澳大灣區企業,按照政策規定在深圳證交所上市。
資料顯示,優必選於2023年12月29日在港交所(00388.HK)上市,成為港股人形機械人「第一股」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.